Healthcare / Medical Instruments & SuppliesShanghai
$24.34
-0.30 (-1.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $18.7M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
54.1x
↑EV/EBITDA
38.1x
↑ROE
5.6%
↑Gross Margin
60.5%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.7%
FCF CAGR
+65.0%
FCF margin
17.4%
FCF / Net income
1.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $219.7M · net income $28.9M · FCF $38.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $219.7M | $219.7M | $203.3M | $200.3M | $196.8M |
| Net Income | $28.9M | $28.9M | $22.8M | $21.5M | $18.0M |
| EBITDA | $41.7M | $41.7M | $28.8M | $27.8M | $22.1M |
| EPS | 0.43 | 0.43 | 0.34 | 0.32 | 0.26 |
| Gross Margin | 60.5% | 60.5% | 59.5% | 56.2% | 53.9% |
| Operating Margin | 11.4% | 11.4% | 8.5% | 8.5% | 6.6% |
| Net Margin | 13.1% | 13.1% | 11.2% | 10.8% | 9.1% |
| Balance Sheet | |||||
| Current Ratio | 4.58 | 4.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $38.3M | $38.3M | $18.7M | $18.2M | $8.5M |
| Returns | |||||
| ROE | 5.6% | 5.6% | 4.6% | 4.4% | 3.8% |
| Valuation | |||||
| P/E | 54.09 | 54.09 | 46.62 | 74.03 | 73.38 |
| EV/EBITDA | 38.07 | 38.07 | 35.05 | 54.32 | 53.00 |
| P/B | 3.18 | 3.18 | 2.15 | 3.25 | 2.78 |
| Growth & Yield | |||||
| Revenue Growth | 8.0% | 8.0% | 1.5% | 1.8% | — |
| EPS Growth | 26.5% | 26.5% | 6.3% | 23.1% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
71.3%
EPS terminal req.
$2.16
Spread vs growth
-44.8%
5Y implied EPS CAGR
43.5%
EPS terminal req.
$2.61
Spread vs growth
-17.0%
10Y implied EPS CAGR
25.6%
EPS terminal req.
$4.21
Spread vs growth
0.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.8%
Start / end P/E
61.1x → 56.6x
EPS bridge
0.34 → 0.43
Residual
-1.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.